BRIEF—Novartis gets temporary reprieve from Gilenya competition in USA

Swiss pharma giant Novartis has been granted an injunction preventing generic versions of its top-selling drug from entering the US market.

A US court has stopped competitors from selling copies of the multiple sclerosis drug Gilenya (fingolimod) in the USA until a patent dispute is resolved, reports Reuters.

The generics companies concerned include Dr Reddy’s Laboratories, Mylan, Torrent Pharma and Aurobindo Pharma.

Worldwide, Gilenya revenue totaled $3.3 billion in 2018.